A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)

NCT00961064 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

Myelodysplastic Syndromes
Thrombocytopenia

Interventions

DRUG: Eltrombopag

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)